Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Restructuring Costs (2016 - 2020)

Historic Restructuring Costs for Tg Therapeutics (TGTX) over the last 5 years, with Q4 2020 value amounting to $16.2 million.

  • Tg Therapeutics' Restructuring Costs rose 45232.56% to $16.2 million in Q4 2020 from the same period last year, while for Dec 2020 it was $41.5 million, marking a year-over-year increase of 33685.43%. This contributed to the annual value of $41.5 million for FY2020, which is 33690.03% up from last year.
  • Per Tg Therapeutics' latest filing, its Restructuring Costs stood at $16.2 million for Q4 2020, which was up 45232.56% from $11.6 million recorded in Q3 2020.
  • In the past 5 years, Tg Therapeutics' Restructuring Costs registered a high of $16.2 million during Q4 2020, and its lowest value of $1.1 million during Q1 2016.
  • In the last 5 years, Tg Therapeutics' Restructuring Costs had a median value of $1.9 million in 2019 and averaged $3.6 million.
  • Its Restructuring Costs has fluctuated over the past 5 years, first plummeted by 802.27% in 2019, then soared by 45232.56% in 2020.
  • Tg Therapeutics' Restructuring Costs (Quarter) stood at $1.3 million in 2016, then skyrocketed by 33.55% to $1.8 million in 2017, then fell by 6.0% to $1.7 million in 2018, then soared by 76.04% to $2.9 million in 2019, then surged by 452.33% to $16.2 million in 2020.
  • Its Restructuring Costs stands at $16.2 million for Q4 2020, versus $11.6 million for Q3 2020 and $8.6 million for Q2 2020.